KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Other Non Operating Income (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Other Non Operating Income for 13 consecutive years, with $1000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 103.03% to $1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14000.0 through Dec 2025, up 128.57% year-over-year, with the annual reading at $14000.0 for FY2025, 128.57% up from the prior year.
  • Other Non Operating Income hit $1000.0 in Q4 2025 for Arbutus Biopharma, up from -$12000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $28000.0 in Q1 2021 to a low of -$33000.0 in Q4 2024.
  • Historically, Other Non Operating Income has averaged -$1421.1 across 5 years, with a median of $1000.0 in 2023.
  • Biggest five-year swings in Other Non Operating Income: surged 450.0% in 2023 and later tumbled 900.0% in 2024.
  • Year by year, Other Non Operating Income stood at $5000.0 in 2021, then crashed by 180.0% to -$4000.0 in 2022, then soared by 450.0% to $14000.0 in 2023, then plummeted by 335.71% to -$33000.0 in 2024, then skyrocketed by 103.03% to $1000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for ABUS at $1000.0 in Q4 2025, -$12000.0 in Q3 2025, and $21000.0 in Q2 2025.